Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.

"Declarations Conflict of interestF. Argüelles-Arias, B. Maldonado, L. Castro, M. Belvis, B. Benítez, and Á. Caunedo, have served as speaker, consultant, and advisory member for, or has received research funding from: MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Tillotts Pharma, Galápagos and Chiesi. T. Valdés-Delgado has served as speaker, consultant, and advisory member for, or has received research funding from: Janssen, Tillotts Pharma, and Galapagos. V. Merino-Bohórquez has served as speaker, consultant, and advisory member for, or has received research funding from: Janssen, Abbvie, Kern Pharma, Pfizer, Sandoz, Novartis, and Galapagos. J. Martín-Manzanares, M.M. Alonso, A. Aguado-Paredes, and M.A. Calleja have no conflict of interest. Ethical approvalThe study protocol was reviewed and approved by the Institutional Review board/ Independent Ethics Committee of Research with Medicines (CEIm) Provincial of Seville. All patients signed the written informed consent before study initiation. Conflict of interest F. Argüelles-Arias, B. Maldonado, L. Castro, M. Belvis, B. Benítez, and Á. Caunedo, have served as speaker, consultant, and advisory member for, or has received research funding from: MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Tillotts Pharma, Galápagos and Chiesi. T. Valdés-Delgado has served as speaker, consultant, and advisory member for, or has received research funding from: Janssen, Tillotts Pharma, and Galapagos. V. Merino-Bohórquez has served as speaker, consultant, and advisory member for, or has received research funding from: Janssen, Abbvie, Kern Pharma, Pfizer, Sandoz, Novartis, and Galapagos. J. Martín-Manzanares, M.M. Alonso, A. Aguado-Paredes, and M.A. Calleja have no conflict of interest."

"Funding Funding for open access publishing: Universidad de Sevilla/CBUA. This study was supported by Grifols."